search
Back to results

Extensively Hydrolyzed Formula: Hypoallergenicity

Primary Purpose

Food Hypersensitivity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Extensively hydrolyzed, whey protein infant formula
Extensively hydrolyzed, casein protein infant formula
Sponsored by
Société des Produits Nestlé (SPN)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Food Hypersensitivity focused on measuring Cow's Milk Allergy, CMA

Eligibility Criteria

2 Months - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Born at term (>36 weeks gestation)
  2. Two (2) months to ≤ 12 years of age at enrollment
  3. Documented Cow's Milk Allergy (CMA) within the 6 months prior to enrollment by:

    1. Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and [detectable serum milk-specific IgE (>0.7 kIU/L) or positive skin prick test (wheal greater than 5 mm]), OR
    2. Physician-supervised oral food challenge that elicited immediate allergic symptoms, OR
    3. Results of laboratory tests highly predictive of clinical reactivity to milk

      • Serum milk IgE ≥15 [kIU/L]or ≥ 5 [kIU/L if younger than 1 year OR,
      • Skin prick tests mean wheal >10 mm
  4. Otherwise healthy
  5. If subject has asthma, atopic dermatitis, and/or rhinitis, must be well controlled
  6. Expected daily intake of at least 8 oz (240 ml) of the study formula during the open challenge phase
  7. Having obtained his/her legal representative's informed consent.

Exclusion Criteria:

  1. Children consuming mother's milk at the time of inclusion and during the trial
  2. Any chromosomal or major congenital anomalies
  3. Any major gastrointestinal disease or abnormalities other than CMA
  4. Chronic medical diseases (ie seizure disorders, chronic lung disease, heart problems (heart murmurs acceptable)
  5. Immunodeficiency
  6. Receiving free amino acid formula
  7. Anti-histamine use in 7 days prior to the first food challenge (eyedrops are acceptable)
  8. Oral steroid use within 14 days prior to enrollment (intranasal and topical corticosteroids are okay)
  9. Unstable asthma
  10. Severe uncontrolled eczema
  11. Recent ( within the last 3 months) severe anaphylactic reaction to milk
  12. Subject who in the Investigator's assessment cannot be expected to adhere to the study protocol
  13. Currently participating in another clinical trial

Sites / Locations

  • Little Rock Allergy & Asthma
  • Pediatric Care Medical Group, Inc
  • Allergy Medical Group of the North Area
  • Brookstone Clinical Research Center
  • Aeroallergy Research Labs of Savannah
  • Idaho Allergy and Asthma Specialists
  • Deaconness Clinic
  • Anderson & Collins Clinical Research
  • Mount Sinai Faculty Practice Associates Pediatric Allergy
  • ENT & Allergy Associates
  • Allergy Partners of Western North Carolina
  • TTS Research
  • Clinical Research Partners
  • Advanced Pediatrics

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Test Formula

Control Formula

Arm Description

New hydrolyzed whey formula

Commercially available hydrolyzed infant formula

Outcomes

Primary Outcome Measures

Hypoallergenicity
To demonstrate that the test formula does not provoke allergenic activity

Secondary Outcome Measures

Digestive Tolerance

Full Information

First Posted
January 14, 2011
Last Updated
November 1, 2013
Sponsor
Société des Produits Nestlé (SPN)
search

1. Study Identification

Unique Protocol Identification Number
NCT01278446
Brief Title
Extensively Hydrolyzed Formula: Hypoallergenicity
Official Title
Evaluation of Hypoallergenicity of a 100% Whey, Extensively Hydrolyzed Infant Formula
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
August 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Société des Produits Nestlé (SPN)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this clinical trial is to determine whether a new extensively hydrolyzed infant formula is hypoallergenic.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Food Hypersensitivity
Keywords
Cow's Milk Allergy, CMA

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized

8. Arms, Groups, and Interventions

Arm Title
Test Formula
Arm Type
Experimental
Arm Description
New hydrolyzed whey formula
Arm Title
Control Formula
Arm Type
Active Comparator
Arm Description
Commercially available hydrolyzed infant formula
Intervention Type
Other
Intervention Name(s)
Extensively hydrolyzed, whey protein infant formula
Other Intervention Name(s)
Baby Formula
Intervention Description
New hydrolyzed formula
Intervention Type
Other
Intervention Name(s)
Extensively hydrolyzed, casein protein infant formula
Other Intervention Name(s)
Baby Formula
Intervention Description
Commercially available hydrolyzed infant formula
Primary Outcome Measure Information:
Title
Hypoallergenicity
Description
To demonstrate that the test formula does not provoke allergenic activity
Time Frame
14 Days
Secondary Outcome Measure Information:
Title
Digestive Tolerance
Time Frame
1 Week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Born at term (>36 weeks gestation) Two (2) months to ≤ 12 years of age at enrollment Documented Cow's Milk Allergy (CMA) within the 6 months prior to enrollment by: Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and [detectable serum milk-specific IgE (>0.7 kIU/L) or positive skin prick test (wheal greater than 5 mm]), OR Physician-supervised oral food challenge that elicited immediate allergic symptoms, OR Results of laboratory tests highly predictive of clinical reactivity to milk Serum milk IgE ≥15 [kIU/L]or ≥ 5 [kIU/L if younger than 1 year OR, Skin prick tests mean wheal >10 mm Otherwise healthy If subject has asthma, atopic dermatitis, and/or rhinitis, must be well controlled Expected daily intake of at least 8 oz (240 ml) of the study formula during the open challenge phase Having obtained his/her legal representative's informed consent. Exclusion Criteria: Children consuming mother's milk at the time of inclusion and during the trial Any chromosomal or major congenital anomalies Any major gastrointestinal disease or abnormalities other than CMA Chronic medical diseases (ie seizure disorders, chronic lung disease, heart problems (heart murmurs acceptable) Immunodeficiency Receiving free amino acid formula Anti-histamine use in 7 days prior to the first food challenge (eyedrops are acceptable) Oral steroid use within 14 days prior to enrollment (intranasal and topical corticosteroids are okay) Unstable asthma Severe uncontrolled eczema Recent ( within the last 3 months) severe anaphylactic reaction to milk Subject who in the Investigator's assessment cannot be expected to adhere to the study protocol Currently participating in another clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jose Saavedra, MD
Organizational Affiliation
Nestle Nutrition
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Anna Nowak-Wegrzyn, MD
Organizational Affiliation
Mount Sinai Department of Pediatrics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Little Rock Allergy & Asthma
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
Pediatric Care Medical Group, Inc
City
Huntington Beach
State/Province
California
Country
United States
Facility Name
Allergy Medical Group of the North Area
City
Roseville
State/Province
California
ZIP/Postal Code
95678
Country
United States
Facility Name
Brookstone Clinical Research Center
City
Columbus
State/Province
Georgia
Country
United States
Facility Name
Aeroallergy Research Labs of Savannah
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
Facility Name
Idaho Allergy and Asthma Specialists
City
Eagle
State/Province
Idaho
ZIP/Postal Code
83616
Country
United States
Facility Name
Deaconness Clinic
City
Evansville
State/Province
Indiana
Country
United States
Facility Name
Anderson & Collins Clinical Research
City
Edison
State/Province
New Jersey
Country
United States
Facility Name
Mount Sinai Faculty Practice Associates Pediatric Allergy
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
ENT & Allergy Associates
City
Newburgh
State/Province
New York
Country
United States
Facility Name
Allergy Partners of Western North Carolina
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28801
Country
United States
Facility Name
TTS Research
City
Boerne
State/Province
Texas
Country
United States
Facility Name
Clinical Research Partners
City
Henrico
State/Province
Virginia
Country
United States
Facility Name
Advanced Pediatrics
City
Vienna
State/Province
Virginia
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Extensively Hydrolyzed Formula: Hypoallergenicity

We'll reach out to this number within 24 hrs